Evidence map›Paper›PMID 31407619›Full record

ArticleJournal of the American Heart Association2019

Inappropriate Left Ventricular Mass and Cardiovascular Disease Events and Mortality in Blacks: The Jackson Heart Study.

D Edmund Anstey, Rikki M Tanner, John N Booth, Adam P Bress, Keith M Diaz, Mario Sims, Gbenga Ogedegbe, Paul Muntner, Marwah Abdalla

Registry-linked trialOpen access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07270367 (Finerenone and Cardiac Remodeling), which is not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07270367 phase3not yet recruitingnot on this mapstarted 2025, after this paper: background citation

Finerenone and Cardiac Remodeling: A Randomized, Double- Blind, Placebo-Controlled Study to Evaluate The Effects of Finerenone on Ventricular Remodeling

TypeinterventionalSponsorSubodh VermaRan2025 to 2030Enrolled156ConditionsHeart FailureArmsFinerenone, Placebo
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 5 institutions in 1 country.

D Edmund AnsteyColumbia University Irving Medical Center New York NY.
Rikki M TannerUniversity of Alabama at Birmingham Birmingham AL.
John N BoothUniversity of Alabama at Birmingham Birmingham AL.
Adam P BressUniversity of Utah School of Medicine Salt Lake City UT.
Keith M DiazColumbia University Irving Medical Center New York NY.
Mario SimsUniversity of Mississippi Medical Center Jackson MS.
Gbenga OgedegbeNew York University School of Medicine New York NY.
Paul MuntnerUniversity of Alabama at Birmingham Birmingham AL.
Marwah AbdallaColumbia University Irving Medical Center New York NY.
Columbia University Irving Medical Center · USUniversity of Alabama at Birmingham · USJackson Memorial Hospital · USNew York University · USUniversity of Utah · US

Funding

Research Training and Education Core (Core D) P50HL120163 · NHLBI · AMERICAN HEART ASSOCIATION · PI BHATNAGAR, ARUNI, ROBERTSON, ROSE MARIE · 2013 to 2017
$20.1M
Social-biological predictors of heterogeneity in CVD risk in African AmericansP60MD002249 · NIMHD · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI DIEZ ROUX, ANA VICTORIA, MENDES DE LEON, CARLOS F. · 2007 to 2016
$15.0M
Molecular and Soc. Determinants of Obesity and Metabolic Disorders in YouthU54MD008176 · NIMHD · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI FOUAD, MONA N. · 2012 to 2016
$13.7M
Incorporation of a Hypertension Working Group into the Jackson Heart StudyR01HL117323 · NHLBI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI LEWIS, CORA E, OGEDEGBE, OLUGBENGA G. · 2013 to 2024
$7.2M
Impact of Prolonged Sedentary Behavior on Cardiac Outcomes and Mortality in Acute Coronary Syndrome PatientsR01HL134985 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI DIAZ, KEITH M · 2017 to 2020
$2.9M
Nocturnal Hypertension and SleepK23HL141682 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ABDALLA, MARWAH · 2019 to 2023
$953k
Genetic ancestry and antihypertensive medication responses in African AmericansK01HL133468 · NHLBI · UNIVERSITY OF UTAH · PI BRESS, ADAM P · 2016 to 2020
$787k
Midcareer Investigator Award in Patient-Oriented Research for Dr. Gbenga OgedegbeK24HL111315 · NHLBI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OGEDEGBE, OLUGBENGA G. · 2012 to 2016
$621k
American Heart Association-American Stroke Association 18AMFDP34380732NHLBI NIH HHS HHSN268201300046CNHLBI NIH HHS HHSN268201300047CNHLBI NIH HHS HHSN268201300048CNHLBI NIH HHS HHSN268201300049CNHLBI NIH HHS HHSN268201300050CNHLBI NIH HHS K01 HL133468NHLBI NIH HHS K23 HL141682NHLBI NIH HHS K24 HL111315NHLBI NIH HHS P50 HL120163NHLBI NIH HHS R01 HL117323NHLBI NIH HHS R01 HL134985NIMHD NIH HHS L60 MD013093NIMHD NIH HHS P60 MD002249NIMHD NIH HHS U54 MD008176
6 · The paper itself

Abstract

Background Left ventricular hypertrophy (LVH) is associated with an increased risk for cardiovascular disease (CVD) events and all-cause mortality. Many individuals without LVH have a left ventricular mass that exceeds the level predicted by their sex, body size, and cardiac workload, a condition called inappropriate left ventricular mass (iLVM). We investigated the association of iLVM with CVD events and all-cause mortality among blacks. Methods and Results We analyzed data from the Jackson Heart Study, a community-based cohort of blacks. The current analysis included 4424 participants without CVD and with an echocardiogram at baseline. Among this cohort, the prevalence of iLVM was 13.8%. There were 262 CVD events and 419 deaths over a median follow-up of 9.7 years (maximum, 12 years). Compared with participants without iLVM, participants with iLVM had a higher rate of CVD events and all-cause mortality. After multivariable adjustment, including for the presence of LVH, iLVM was associated with an increased risk of CVD events (hazard ratio, 1.87; 95% CI, 1.33-2.62). The multivariable-adjusted hazard ratio for all-cause mortality was 1.29 (95% CI, 0.98-1.70). Among participants without and with LVH, the multivariable-adjusted hazard ratios of iLVM for CVD events were 2.53 (95% CI, 1.68-3.81) and 1.21 (95% CI, 0.74-2.00), respectively (P

Indexed as

MortalityAdultAgedAntihypertensive AgentsBlack or African AmericanCardiovascular DiseasesCause of DeathCohort StudiesEchocardiographyFemaleHeart VentriclesHumansHypertensionHypertrophy, Left VentricularLongitudinal StudiesMaleAntihypertensive Agentsblackcardiovascular diseaseinappropriate left ventricular massleft ventricular hypertrophymortality

Identifiers

PMID31407619
PMCPMC6759894
OpenAlexW2967510728

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.